Author Archives: admin


Radiation to treat pediatric cancers may have lasting impact on heart and metabolic health – Science Codex

Bottom Line: Adult survivors of childhood abdominal and pelvic cancers who had been treated with radiation therapy experienced abnormalities in body composition and had worse cardiometabolic health compared with the general population.

Journal in Which the Study was Published: Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research

Author: Carmen Wilson, PhD, assistant member in the Epidemiology and Cancer Control department at St. Jude Children's Research Hospital

Background: "Body composition abnormalities and cardiometabolic impairments are of concern among survivors given that in the general population, these conditions increase the risk of developing life-threatening diseases including cardiovascular disease and type 2 diabetes," said Wilson. The impacts of radiation therapy on metabolic health have been previously reported for survivors of pediatric leukemia, brain tumors, and hematopoietic stem cell transplants, but the impacts on survivors of pediatric abdominal and pelvic tumors remained unclear, she said.

How the Study was Conducted: In this study, Wilson and colleagues assessed 431 adult survivors of pediatric abdominal or pelvic solid tumors who had been previously treated at St. Jude Children's Research Hospital. The median age of participants during the study was 29.9 years. The most frequent childhood diagnoses were neuroblastoma, Wilms tumor, and germ cell tumor, and the median age of participants at diagnosis was 3.6 years. Approximately 37 and 36 percent of participants had received abdominal and pelvic radiation therapy, respectively, as part of their treatment.

To assess the impacts of radiation therapy, the authors compared the participants' body composition, metabolic abnormalities, and physical function to those of the general population, using age-, sex-, and ethnicity-matched data from the 2013 to 2014 National Health and Nutrition Examination Survey (NHANES).

Results: Wilson and colleagues found that compared with data from NHANES, the survivors in their study were significantly more likely to have insulin resistance (33.8 percent vs. 40.6 percent), high triglycerides (10.02 percent vs. 18.4 percent), and low levels of high-density lipoproteins, commonly referred to as "good cholesterol" (28.9 percent vs. 33.5 percent). There were no significant differences in the levels of low-density lipoproteins ("bad cholesterol") between survivors and the general population.

The analyses also demonstrated that survivors of abdominal and pelvic solid tumors had lower relative lean body mass than the general population and that the lower relative lean body mass was associated with the dose of prior abdominal or pelvic radiation. Lean body mass, which measures the non-fat content of the body, is related to basal metabolic rate; therefore, an individual with lower lean body mass burns fewer calories while resting than someone with higher lean body mass, Wilson explained.

There was no significant difference in relative fat body mass between survivors and the general population; however, survivors who had high relative fat mass had reduced quadricep strength and poor physical performance (as measured by a sit-and-reach test and distance covered during a six-minute walk) compared with survivors who had low relative fat mass.

Author's Comments: "It is possible that abdominal and pelvic-directed radiation therapy damages postural muscles or subtly impairs sex hormone production, ultimately affecting muscle mass," said Wilson. She explained that radiation therapy has been shown to cause muscle injury, resulting in muscle fiber loss and loss of muscle regenerative cells, in animal studies. Wilson added that lifestyle choices may also impact relative lean mass and cardiometabolic health among survivors.

Wilson suggested that future research could examine the impact of radiation therapy and other cancer treatments on fat distribution across the body since increased abdominal obesity has been shown to be a better predictor of adverse health effects than measures of overall obesity.

In addition, Wilson is interested in exploring how interventions directed at lifestyle behaviors could improve lean mass and decrease fat mass among survivors of pediatric cancers. "While it may not be possible to avoid radiation therapy as a key treatment for many solid tumors, early research suggests that resistance training interventions in survivors increase lean mass," said Wilson. "Further work is needed to see if training would also impact cardiometabolic impairments in this population."

Study Limitations: A limitation of the study is that cardiometabolic outcomes may have been measured differently in the study cohort compared with those surveyed by NHANES.

Here is the original post:
Radiation to treat pediatric cancers may have lasting impact on heart and metabolic health - Science Codex

Scientists hope to bring Malaysian rhinoceros back from extinction with stem cell technology – The Province

The last Sumatran rhinoceros individual of Malaysia Iman, photographed at her sanctuary on the island of Borneo in October 2019. KAISA SIREN / LEHTIKUVA

Some skin, eggs and tissue samples are all that remain of Malaysias last rhino, Iman, who died last November after years of failed breeding attempts.

Now scientists are pinning their hopes on experimental stem cell technology to bring back the Malaysian variant of the Sumatran rhinoceros, making use of cells from Iman and two other dead rhinos.

Im very confident, molecular biologist Muhammad Lokman Md Isa told Reuters in his laboratory at the International Islamic University of Malaysia.

If everything is functioning, works well and everybody supports us, its not impossible.

The smallest among the worlds rhinos, the Sumatran species was declared extinct in the wild in Malaysia in 2015. Once it had roamed across Asia, but hunting and forest clearance reduced its numbers to just 80 in neighboring Indonesia.

Iman, 25, died in a nature reserve on Borneo island, following massive blood loss caused by uterine tumors, within six months of the death of Malaysias last male rhino, Tam.

Efforts to get the two to breed had not worked.

He was the equivalent of a 70-year-old man, so of course you dont expect the sperm to be all that good, said John Payne of the Borneo Rhino Alliance (BORA), who has campaigned for about four decades to save Malaysias rhinos.

It was obvious that, to increase the chances of success, one should get sperm and eggs from the rhinos in Indonesia. But right till today, Indonesia is still not keen on this.

ACROSS THE BORDER

Indonesias environment ministry disputed accusations of cross-border rivalry as a reason why Malaysias rhinos died out, saying talks continue on ways to work with conservationists in the neighboring southeast Asian nation.

Because this is part of diplomatic relations, the implementation must be in accordance with the regulation of each country, said Indra Exploitasia, the ministrys director for biodiversity conservation.

The Malaysian scientists plan to use cells from the dead rhinos to produce sperm and eggs that will yield test-tube babies to be implanted into a living animal or a closely related species, such as the horse.

The plan is similar to one for the African northern white rhinoceros, which number just two. Researchers in that effort reported some success in 2018 in producing embyronic stem cells for the southern white rhino.

But the process is still far from producing a whole new animal, say Thomas Hildebrandt and Cesare Galli, the scientists leading the research.

And even if it worked, the animals lack of genetic diversity could pose a threat to long-term survival, Galli told Reuters.

Indonesian scientist Arief Boediono is among those helping in Malaysia, hoping success will provide lessons to help his countrys rhinos.

It may take five, 10, 20 years, I dont know, Arief added. But there has already been some success involving lab rats in Japan, so that means there is a chance.

Japanese researchers have grown teeth and organs such as pancreas and kidneys using embryonic stem cells from rats and mice in efforts to grow replacement human organs.

For now, however, Imans hide will be stuffed and put on display alongside Tam in a Borneo museum.

Go here to see the original:
Scientists hope to bring Malaysian rhinoceros back from extinction with stem cell technology - The Province

Cell Isolation/Cell Separation Market Research Report by Product, by Cell Type, by Cell Source, by Technique, by Application, by End User – Global…

August 13, 2020 05:16 ET | Source: ReportLinker

New York, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Isolation/Cell Separation Market Research Report by Product, by Cell Type, by Cell Source, by Technique, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913776/?utm_source=GNW

The Global Cell Isolation/Cell Separation Market is expected to grow from USD 6,356.88 Million in 2019 to USD 14,485.68 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 14.71%.

Market Segmentation & Coverage: This research report categorizes the Cell Isolation/Cell Separation to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the Cell Isolation/Cell Separation Market studied across Consumables and Instruments. The Consumables further studied across Beads, Disposables, and Reagents, Kits, Media, and Sera. The Instruments further studied across Centrifuges, Filtration Systems, Flow Cytometers, and Magnetic-Activated Cell Separator Systems.

Based on Cell Type, the Cell Isolation/Cell Separation Market studied across Animal Cells and Human Cells. The Human Cells further studied across Differentiated Cells and Stem Cells.

Based on Cell Source, the Cell Isolation/Cell Separation Market studied across Adipose Tissue, Bone Marrow, and Cord Blood/Embryonic Stem Cells.

Based on Technique, the Cell Isolation/Cell Separation Market studied across Centrifugation-Based Cell Isolation, Filtration-Based Cell Isolation, and Surface Marker-Based Cell Isolation.

Based on Application, the Cell Isolation/Cell Separation Market studied across Biomolecule Isolation, Cancer Research, In Vitro Diagnostics, Stem Cell Research, and Tissue Regeneration & Regenerative Medicine.

Based on End User, the Cell Isolation/Cell Separation Market studied across Biotechnology & Biopharmaceutical Companies, Hospitals & Diagnostic Laboratories, and Research Laboratories & Institutes.

Based on Geography, the Cell Isolation/Cell Separation Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Isolation/Cell Separation Market including Beckman Coulter Inc. (Subsidiary of Danaher Corporation), Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., GE Healthcare, Merck KGaA, Miltenyi Biotec, Pluriselect Life Science Ug (Haftungsbeschrnkt) & Co. Kg, Stemcell Technologies, Inc., Terumo Bct, and Thermo Fisher Scientific, Inc..

FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cell Isolation/Cell Separation Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as: 1. What is the market size and forecast of the Global Cell Isolation/Cell Separation Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cell Isolation/Cell Separation Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cell Isolation/Cell Separation Market? 4. What is the competitive strategic window for opportunities in the Global Cell Isolation/Cell Separation Market? 5. What are the technology trends and regulatory frameworks in the Global Cell Isolation/Cell Separation Market? 6. What are the modes and strategic moves considered suitable for entering the Global Cell Isolation/Cell Separation Market? Read the full report: https://www.reportlinker.com/p05913776/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original here:
Cell Isolation/Cell Separation Market Research Report by Product, by Cell Type, by Cell Source, by Technique, by Application, by End User - Global...

Stem Cell Therapy Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 – Bulletin Line

Allosource

Competitive Landscape of the Stem Cell Therapy Market:

The market for the Stem Cell Therapy industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry. The report also covers their mergers and acquisitions, collaborations, joint ventures, partnerships, product launches, and agreements undertaken in order to gain a substantial market size and a global position.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Regional Analysis of Stem Cell Therapy Market:

A brief overview of the regional landscape:

From a geographical perspective, the Stem Cell Therapy Market is partitioned into

North America o U.S. o Canada o Mexico Europe o Germany o UK o France o Rest of Europe Asia Pacific o China o Japan o India o Rest of Asia Pacific Rest of the World

Key coverage of the report:

Other important inclusions in Stem Cell Therapy Market:

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Read the original:
Stem Cell Therapy Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line

Scientists distinguish new method that causes leukemia – Laboratory Equipment Magazine,Microbiology and Healthcare News,Scientific Equipment News -…

Every year, 1.1 million new cases of blood cancers are diagnosed globally. Currently, chemotherapy remains the most common and efficient plan of treatment. On the other hand, the development of aggressive types of leukemia in adults stimulates a need for early detection and new therapeutic approaches to achieve better clinical outcomes.

In a novel step ahead, researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have identified covalently closed circular RNAs (circRNAs) from key genes involved in embryonic growth and provided greater understanding of their functions in haematological malignancies.

This work has provided insights into a new mechanism for the regulation of H2AK119ub levels in hematopoietic progenitors via interaction of circASXL1-1 and BAP1,-Sudhakar Jha, Assistant Professor, Cancer Science Institute of Singapore, National University of Singapore

Mutations in additional sex combs-like 1 (ASXL1) receptor, an epigenetics remodeler, are found in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS), and are associated with poor overall survival. Lately, the ASXL1 gene locus was shown to undergo alternative splicing to produce circRNAs.

While previous studies on circRNAs have mostly been concentrated on understanding the roots of the non-coding RNAs, the CSI Singapore research team headed by Assistant Professor Sudhakar Jha investigated the function of circRNAs in modulating the epigenetics landscape as well as the effects on differentiation in hematopoietic development and leukemogenesis.

The findings of this study were published in the prestigious scientific journal Haematologica in July 2020.

New mechanism accountable for leukemia development CircRNAs have been shown to have higher equilibrium, are plentiful, and highly conserved compared to linear RNAs.

In addition, they can be detected in extracellular vesicles, exosomes and blood plasma thus highlighting their possible as non invasive biomarkers. During RNA sequencing, the research team discovered circRNA isoforms in the ASXL1 gene locus.

The teams analysis made inroads into understanding the use of circASXL1-1 in leukemia. Their statistics show that depletion of circASXL1-1 led to decreased H2AK119 ubiquitination (H2AK119ub) and this had been through BRCA-1 related protein (BAP1) action, a deubiquitinating enzyme and a significant epigenetic regulator at leukemia. Tapping on the newly established comprehension, the research team aims to identify genes involved in myeloid differentiation program of haematopoietic stem cells (HSCs).

These enzymes can in turn be targeted to restore the normal path of differentiation in leukemia or to assist induce apoptosis of abnormally differentiated cells. The epigenetic signature recognized may thus pave the way for future therapeutic improvements ofepi-drugs.

Moving forward, the research team intends to create data supporting the use of circASXL1-1 in antisense therapy for malignant and non-malignant blood disorders using the recently obtained knowledge. More to the point, findings from this study will lay the foundation for the development of new RNA-based therapeutics for leukemia.

Source:

Journal reference:

Jadhav, S. P., circASXL1-1 regulates BAP1 deubiquitinase activity in leukemia. Haematologica.doi.org/10.3324/haematol.2019.225961.

Continue reading here:
Scientists distinguish new method that causes leukemia - Laboratory Equipment Magazine,Microbiology and Healthcare News,Scientific Equipment News -...

CurePSP Partners With Rainwater to Support Pioneering Neurodegeneration Research – Yahoo Finance

Study will use miniature brains cultivated from stem cells to study protein mutations

CurePSP has awarded a $100,000 grant for a potentially breakthrough study that will employ 3D organoid models that have been shown to produce structures similar to those seen in the human brain to understand the effects of protein mutations that are associated with neurodegeneration.

The grant will assist the Tau Consortium Stem Cell Group, created and supported by the Rainwater Charitable Foundation, in helping to extend the scope of this multidisciplinary and multiyear study. The funding has been provided through generous donations from Frank Semcer, Sr., in honor of his wife Mary Jane Semcer; and from F. Jackson Phillips, in honor of his wife, Linda A. Phillips. Both women have received diagnoses of progressive supranuclear palsy (PSP), a rare form of neurodegeneration that involves pathological accumulation of the tau protein, a type of naturally occurring protein in the brain. CurePSPs grant was made under the auspices of the Prime of Life Brain Initiative, a collaborative venture with Rainwater to advance research into neurodegeneration.

The CurePSP grant will support research conducted by investigators of the Tau Consortium Stem Cell Group including Dr. Sally Temple of the Neural Stem Cell Institute, Dr. Alison Goate of the Ichan School of Medicine at Mount Sinai, Dr. Justin Ichida of the University of Southern California, Dr. Celeste Karch of Washington University, and Dr. Martin Kampmann of the University of California San Francisco.

Sometimes called "disease in a dish," 3D organoids are grown from skin-derived stem cells of patients and healthy individuals. Studies using these patient derived cell cultures aim to avoid some of the challenges and limitations of using animal models in research, including lack of construct validity of data (the degree to which data measures what it claims to be measuring) collected from animal studies when projected to humans. Since the first development of 3D neuronal cell cultures (organoids) less than 10 years ago, efforts have focused on the standardization and reproducibility of organoids protocols. Even more recently, genetic engineering techniques (CRISPR) and sequencing methods such as single-cell RNA sequencing have enabled greater robustness and a deeper understanding of these personalized human-derived disease models.

Dr. Kristophe J. Diaz, Vice President Scientific Affairs for CurePSP, said, "The use of human-derived disease models as opposed to reliance solely on animal models is a crucial step in the study of complex neurodegenerative disorders. We are thrilled to participate in this landmark study with the Tau Consortium and thank the Semcers and Phillips for their support."

Patrick Brannelly, Managing Director of the Tau Consortium, added, "PSP has become a key focus in the study of neurodegeneration for several of the worlds best academic institutions. CurePSPs collaboration in this study is greatly valued. We look forward to our continued partnership through the Prime of Life Brain Initiative."

CurePSP was an early supporter of the work of the Neural Stem Cell Institute with grants to Dr. David Butler for his work in developing therapeutic agents to prevent tau protein accumulation with novel antibody-based reagents called intrabodies and to Dr. Mo Liu for her pioneering work in developing PSP organoids.

About CurePSP

CurePSP is the nonprofit advocacy organization focused on progressive supranuclear palsy, corticobasal degeneration, and other prime of life neurodegenerative diseases, a spectrum of fatal brain disorders that often strike during a persons most productive and rewarding years. Currently, there is no effective treatment or cure for these diseases, which affect more than 150,000 people in the U.S. alone. Since it was founded in 1990, CurePSP has funded nearly 200 research studies and is the leading source of information and support for patients and their families, other caregivers, researchers and doctors, and allied healthcare professionals. CurePSP is based in New York City. Please visit http://www.curepsp.org for more information.

About the Rainwater Charitable Foundation

The Rainwater Charitable Foundation was created in the early 1990s by renowned investor and philanthropist Richard E. Rainwater. The foundation supports a range of different programs in K-12 education, medical research, and other worthy causes. In order to deliver on its mission to accelerate the development of new diagnostics and treatments for tau-related neurodegenerative disorders, the Rainwater Charitable Foundation Medical Research team manages the Tau Consortium and the Rainwater Prize Program for advances in neurodegenerative disease research. With more than $100 million invested to date, Rainwater support has helped to advance eight treatments into human trials. For more information, please visit http://www.tauconsortium.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005112/en/

Contacts

David Kemp kemp@curepsp.org 802-734-1185

Visit link:
CurePSP Partners With Rainwater to Support Pioneering Neurodegeneration Research - Yahoo Finance

A breakthrough drug saved the lives of every critical coronavirus patient who took it – BGR

We may be wrong to expect a miracle cure for COVID-19. Thats because it might not be just one breakthrough drug that delivers the miracle, which is the prevention of life-threatening symptoms. We may end up with several new drugs for COVID-19 that would work independently or in tandem with others to save the lives of patients who develop complications.

Recent studies showed that several therapies can reduce COVID-19 mortality to some degree. But neither remdesivir nor dexamethasone can prevent deaths completely. This is where narsoplimab may come to the rescue, a monoclonal antibody drug thats not supposed to block the coronavirus from infecting cells like other monoclonal therapies being tested for COVID-19. Instead, this drug protects the integrity of blood vessels and helps prevent clotting. Narsoplimab saved the lives of every one of the critical COVID-19 patients who were included in a limited trial in Bergamo, Italy, one of the early epicenters of the European COVID-19 epidemic.

Made by Omeros, narsoplimab was initially devised for other medical conditions that cause damage to the blood vessels, but doctors involved with previous clinical testing thought the drug might also work on COVID-19 cases. Dr. Alessandro Rambaldi from the Papa Giovanni XXIII hospital in Bergamo was involved in a stem-cell trial for narsoplimab before COVID-19, Omeros explained in a press release. The doctor asked Omeros to offer the drug to six COVID-19 patients in critical condition, who needed mechanical ventilators to breathe.

These patients developed Acute Respiratory Distress Syndrome (ARDS), one of the COVID-19 complications that can lead to death. The patients were aged 47 to 63, all had comorbidities, and five of them were men. The researchers administered narsoplimab 48 hours after mechanical ventilation had started, and then all the patients received the drug twice a week for two to four weeks.

All the patients recovered and survived COVID-19, but two of them were hospitalized for about a month after narsoplimab treatment began. Another spent some three months in the hospital after the first dose.

From the study: Clinical outcome of patients treated with narsoplimab. The bar colors indicate the different oxygen support (CPAP, yellow; mechanical ventilation with intubation, red; non-rebreather oxygen mask, green; low flow oxygen by nasal cannula, light green; room air, blue). Narsoplimab doses are marked by blue arrows. Black circles indicate the beginning of steroid treatment (day +2 in patients #4 and #6, day +4 in patient #5 and day +10 in patient #2 and #3). Black asterisk denotes discharge from hospital. CPAP=continuous positive airway pressure; NRM=non-rebreather oxygen mask; VM=Venturi mask; TEP=pulmonary thromboembolism. Image source: Omeros via ScienceDirect

Endothelial injury appears to be caused by direct viral infection in COVID-19, the researchers wrote in the paper, and that damage can be measured with the help of several parameters. The doctors measured those parameters, which proved the drug reduced the cellular damage inside the blood vessels. Narsoplimab also prevents blood clotting, the researchers say, and it might prevent so-called cytokine storms, the overreaction of a patients immune system that can be fatal.

The temporal improvement of IL-6 and IL-8 with narsoplimab treatment suggests that lectin pathway activation may precede cytokine elevation in COVID-19 and that lectin pathway inhibition has a beneficial effect on the cytokine storm described in patients with COVID-19 infection

The researchers say the drug was well tolerated and there were no side-effects. The study also reveals that five of the six patients received steroids at the hospital, with two of them getting the drug after their condition improved significantly (patients 2 and 3 in the graphic above).

One downside of the study is that it wasnt a double-blind, placebo-controlled, randomized trial. But the researchers compared the six patients with two control groups that met similar criteria and characteristics, which showed mortality rates of 32% and 53%.

The patients that we treated with narsoplimab were critically ill, and the uniformly successful outcomes were truly impressive,Rambaldi said. Also of importance in this terribly sick population studied, the drug was well tolerated, showing no adverse effects. The pathophysiology of COVID-19 appears to be consistent with that of stem cell transplant-associated TMA, and the mechanism of the lectin pathway inhibitor narsoplimab looks to be well suited to treat the often-lethal manifestations of both disorders. The outcomes in these six patients provide further evidence of the potential role of narsoplimab in treating diseases caused by endothelial damage.

The drug is under review for federal approval, The Seattle Times reports, and its considered for federal support under the Operation Warp Speed initiative.

More research will be required before the drug can be widely used to treat severe COVID-19 cases. If the drug can indeed deliver the same response in most patients who develop complications, it could potentially save a lot of lives. That said, its unclear how easy it is to manufacture or how much it will cost.

The Omeros study will be published in the peer-reviewed journal Immunology and is available in pre-print form at this link.

Chris Smith started writing about gadgets as a hobby, and before he knew it he was sharing his views on tech stuff with readers around the world. Whenever he's not writing about gadgets he miserably fails to stay away from them, although he desperately tries. But that's not necessarily a bad thing.

The rest is here:
A breakthrough drug saved the lives of every critical coronavirus patient who took it - BGR

Covid-19 Impact: Patients with aplastic anemia at receiving end – Daily Pioneer

Poverty, Government apathy and Covid-19 induced-lockdown restricting travel proved fatal for little Kishan, a 11-year-old boy suffering from Aplastic anemia, a life-threatening blood disorder condition in which the bone marrow and stem cells do not produce enough blood cells

Facing severe financial constraints and waiting timely medical aid, first at Safdarjung Hospital and then AIIMS, both Government hospitals in Delhi, Kishans life was cut short in March this year amid Covid-19 pandemic.

However, Kishans is not a lone case. Dr Nita Radhakrishnan, paediatric haemato-oncologist at Super Speciality Paediatric Hospital, Noida, Uttar Pradesh says that as the deadly Coronavirus captured the attention of the nation in the most unprecedented manner, the non-Covid patients particularly those with the Aplastic anemia have suffered the most in the crisis.

She gave instances of her two teenage patients who succumbed to blood disorder in the Covid catastrophe. Manish (name change), a 17-year-old was suffering with on-and-off fever, gum bleeding, and melena for three months, he came to us in December last year just when Coronavirus had started spreading its tentacles from China to other parts of the world.

The boy was diagnosed with severe Aplastic anemia and was recommended requisite treatment like regular hospital visit for red cell transfusion before he could be given bone marrow transplant (BMT), a life saving treatment.

However, while the family was not able to visit our hospital in Noida due to the covid-lockdown, no blood products were available at the hospital near to the patients locality. In want of blood, Manish could not survive more days.

13-year-old Suresh (name change) too faced similar fate. While Government funds could not be sanctioned for his BMT in time the boy could not visit the Noida hospital for further follow-up due to travel restrictions. Two weeks later, Suresh died due to hemorrhage at his native place, lamented the doctor.

These are just two reported cases from the NCR hospital located near the countrys capital. Several have gone unreported. The Government has no policy nor any long-term plan for such patients.

The prognosis of severe aplastic anemia in our country is dismal. The incidence of 46 per million population of childhood aplastic anemia in India and other Asian countries is higher than what is observed in the West, explains Dr Radhakrishnan. The scenario is gloomy for the patients afflicted with the disease as they need blood transfusion almost every 20 days.

A significant proportion of patients of aplastic anemia (around 30 per cent) die before any definitive treatment is initiated. A study by AIIMS based on a recent series of patients follow-up showed that out of 1501 patients diagnosed over last seven years, only 303 ie 20 per cent received the definitive treatment modalities through either BMT or IST with ATG and cyclosporine, says Dr Radhakrishnan in her case report Aplastic anemia: Non-COVID casualties in the Covid-19 era, published in the latest edition of Indian Journal of Palliative Care.

The doctors have sought urgent intervention. Dr Radhakrishnan says that as we await the peak of Covid-19 in our country and possibly secondary and tertiary waves thereafter, patients with aplastic anemia who are the sickest among all hematological illnesses would benefit greatly from urgent intervention from the Government to ensure timely treatment.

Those suffering with Aplastic anemia, there is mostly delay in diagnosis, delay in initiation of treatment due to monetary constraints, non-inclusion of the disease under government schemes such as Ayushman Bharat and NHM and delay in sanction of money from other Government schemes such as Rashtriya Arogya Nidhi, Chief Minister and Prime Ministers relief fund often due to lack of proper documents, she added.

Delay means, risk of contracting fungal infections and increase in drug-resistant bacterial infections increase which further hamper the treatment, point out Dr Ravi Shankar and Dr Savitri Singh in the study.

Though the Union Health Ministry, after few days of lockdown period, issued directions for continuing treatment for essential health services including reproductive and maternal health services, newborn care, severe malnutrition, and NCDs including cancer care, palliative care, dialysis, and care of disabled, unfortunately those with Aplastic anemia got ignored.

This despite of the fact that these patients are at the highest risk of death following a break in the treatment of few weeks, notes Dr Radhakrishnan.

Because of the closure of offices and absence of staff, during the lockdown period, there was delay in sanction of usual grants due to the lockdown of offices and inability in generating documents such as income certificate from the tehsils.

For instance, Suresh and Manish, both our patients received the Government grant after around 34 months of applying for the same. But both had died before they could reach the hospital for treatment, lamented the hematologist.

See the original post:
Covid-19 Impact: Patients with aplastic anemia at receiving end - Daily Pioneer

BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S. – Stockhouse

- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients -

- First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with Plinabulin and Pegfilgrastim, Despite Experiencing Grade 4 Neutropenia in Cycle 1 with Pegfilgrastim Alone -

NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company” or BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has initiated an Expanded Access Program (EAP) to enable doctors across the U.S. to use BeyondSpring’s late-stage asset, Plinabulin, to prevent cancer patients’ chemotherapy-induced neutropenia (CIN), both alone and in combination with G-CSFs (the current standard of care), during the COVID-19 pandemic. Dr. Emad Ibrahim enrolled the first patient at Redlands Community Hospital in California on July 28, 2020.

In response to COVID-19, the National Comprehensive Cancer Network (NCCN) recently updated its treatment guidelines for the prophylaxis of CIN, with the objective of preserving hospital and ER resources for COVID-19 patients and maximizing protection for cancer patients against CIN development. This is designed to help necessitate healthcare interactions, and avoidance of hospital / ER visits will also minimize cancer patients’ risk of contracting COVID-19. In light of these NCCN guideline updates, BeyondSpring initiated an Expanded Access Program to enable the use of Plinabulin by oncologists to better protect cancer patients against CIN with the use of myelosuppressive chemotherapies under the current COVID-19 challenges.

Dr. Emad Ibrahim enrolled the first patient under this EAP at Redlands Community Hospital in California:

The recent updates to the NCCN guidelines aim to protect cancer patients from developing CIN in the most effective way possible and enable the healthcare system to reserve precious resources for COVID-19 patients,” said Ramon Mohanlal, BeyondSpring’s Chief Medical Officer and Executive Vice President, Research and Development. In our CIN studies, Plinabulin, in combination with Pegfilgrastim, provided superior protection against CIN, compared to the standard of care alone. The observation in this first EAP patient who completely avoided Grade 4 CIN when given Plinabulin and Pegfilgrastim is a significant achievement for us. At BeyondSpring, we strive to play our part in serving patients and healthcare providers to the highest degree while working through the many challenges imposed by COVID-19.”

Preventing CIN during chemotherapy is extremely important, as this will enable cancer patients to receive the full regimen of chemotherapy and achieve treatment goals. The onset of CIN is the No. 1 reason for treatment modifications, such as downgrading the strength of chemotherapy or stopping chemotherapy altogether. When a patient develops CIN, the treating physician is required to delay the next round of chemotherapy until a patient’s white blood cell count recovers. These changes can have a profoundly negative impact on patient outcomes.

For more information on BeyondSpring’s Plinabulin Expanded Access Program, please visit http://www.beyondspringpharma.com/EAP/. Supplies may be limited.

If you are a physician in the U.S. who would like to request Plinabulin EAP access for your patient, please email expandedaccess@beyondspringpharma.com.

About BeyondSpring Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring’s first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen dose’s decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a pipeline drug,” Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed molecular glue” that uses the protein degradation pathway.

About Plinabulin Plinabulin, BeyondSpring’s lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulin’s CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.

Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications 212.896.1241 / 212.896.1276 ckasunich@kcsa.com / rcona@kcsa.com

More:
BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S. - Stockhouse

Global Manufacturer of COVID-19 Test Kits, Partners with HBCUs to… – Diverse: Issues in Higher Education

August 12, 2020 | :

by B. Denise Hawkins

Its August and many colleges and universities continue to pivot or weigh the risk that come with re-opening this fall, during a pandemic. Without a vaccine, most infectious disease experts say that a plan to test every few days for COVID-19 is the safest way for institutions to bring their students back to campus. But its also a costly venture that few of them say they can afford to provide, among them are historically Black colleges and universities (HBCUs).

On Wednesday, Thermo Fisher Scientific, the worlds largest maker of scientific tools, announced a project to support testing, at no-cost, to the nations HBCUs, including establishing national HBCU testing centers to process COVID-19 tests and provide timely results throughout the academic year.

Fred Lowery

Through an initiative called The Just Project, named after pioneering cell biologist Ernest Everett Just who served on the Howard University faculty for more than three decades, Thermo Fisher plans to donate $15 million in diagnostic instruments, test kits and related supplies. The multi-billion-dollar company will also provide technical assistance to HBCUs that want to establish or expand their laboratories to provide regular on-campus COVID-19 testing. Five HBCUsHoward University, Morehouse School of Medicine, Meharry Medical College, Xavier University of Louisiana and Hampton Universitywill be the first to receive donations. Their laboratories, along with those at other Black colleges and universities, will obtain samples on their campuses. Then samples will be collected from HBCUs and shipped to their assigned testing center. Over the next few weeks, more institutions are expected to join the project as national testing hubs. These campus labs can be operational as early as next week, said Fred Lowery, senior vice president and president, Life Sciences Solutions and Laboratory Products at Thermo Fisher.

With a new and uncertain fall semester already underway for many HBCU campuses, Lowery said he continues to spread the word about The Just Project and the access it provides to COVID-19 testing for populations who have been hard hit by the pandemic and the coronavirus.

HBCU presidents have been incredibly supportive, he said, and so far, about 30% have shown interest.

Dr. James E.K. Hildreth, the president and CEO of Meharry Medical School in Nashville, Tenn., said he has been fielding calls and speaking with fellow HBCU presidents about the testing opportunity that could save them thousands of dollarsmoney that most small Black colleges dont have.

I anticipate that buy-in will grow, Hildreth said. Early in the pandemic, he pushed to bring free COVID-19 testing to overlooked communities of color in Nashville that were most at risk for contracting the virus. Now, he said that reach will include all HBCUs and provide a training ground for his students long after COVID-19.

This partnership with Thermo Fisher and the other HBCU medical schools is pretty amazing, said Hildreth. [Thermo Fisher] wants to make sure that Black colleges and universities have the same ability to bring their kids back to campus safely as majority schools do.

Since the early months of the COVID-19 pandemic, testing for the coronavirus in the U.S. has been problematic and worrisome. Today, testing levels are dropping even as infections remain high and the death toll in the country rises by more than 1,000 a day. Long wait times for results have been partly to blame. The Waltham, Mass.-based Thermo Fisher says that it has the capacity to produce more than 10 million tests per week.

For some HBCUs, the capacity to provide COVID-19 testing for their students, faculty and staff was a huge factor that determined whether they would reopen for in-person classes or go virtual. After releasing a carefully crafted reopening plan in early June, on August 11, Morgan State University in Baltimore Md., for example, announced plans for a virtual fall semester and limited on-campus operation and housing. The University said its shift followed the release of a recent study from Yale University indicating that college students would need to be tested every two to three days for their institutions to safely reopen. Forging ahead, the historically Black Delaware State University has set a high bar when it comes to campus testing. When it plans to reopen on August 25, DSU is counting on its new COVID-19 testing model and a quarantine dorm for safe passage through the fall semester. Assurance is also coming from its partnership with the new nonprofit Testing for America,which will provide free, regularcoronavirustests for students, faculty and staff that return results in 24 to 34 hours.

The pandemic has disproportionately affected the Black community, and historically Black colleges and universities have taken a leadership role in making testing available in order to safely reopen this fall, said Lowery. These schools play an important role in closing the achievement gap in America and consistently train talented STEM professionals who are invaluable to companies like ours seeking to attract top talent and build a more inclusive workplace.Given the value we place on recruiting diverse talent, we have also committed to hiring at least 500 students from these institutions over the next three years.

Added Dr. Wayne A. I. Frederick, president of Howard University: Historically Black colleges and universities have produced talented doctors, public health experts and engineers, many of whom are contributing to the fight against COVID-19, he said. We are grateful to Thermo Fisher for supporting a testing center on our campus, which will allow us to continue to monitor the health of our academic community.

Read more from the original source:
Global Manufacturer of COVID-19 Test Kits, Partners with HBCUs to... - Diverse: Issues in Higher Education